Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 5,280 Shares

March 17, 2026 by InsiderTrades.com

Key Points

CEO sale on March 13: CEO Jack Bendheim sold 5,280 shares at an average price of $48.91 for $258,244.80, leaving him with 96,200 shares valued at about $4.71 million (a 5.20% reduction in his position).
Larger selling pattern: Bendheim has been steadily selling since early February, disposing of roughly $11.7 million of stock across multiple trades, indicating significant insider selling activity over the past month.
Company fundamentals: Phibro recently beat quarterly estimates (EPS $0.87 vs. $0.69; revenue $373.9M vs. $355.6M), set FY2026 guidance of $2.93–$3.10 EPS, pays a $0.12 quarterly dividend (0.9% yield), and has a market cap of about $2.07 billion with a P/E of 22.74.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 5,280 shares of the business's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $48.91, for a total value of $258,244.80. Following the completion of the sale, the chief executive officer directly owned 96,200 shares in the company, valued at approximately $4,705,142. The trade was a 5.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total value of $378,259.20.
On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total value of $361,644.80.
On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total value of $361,856.00.
On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total value of $365,798.40.
On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total value of $732,178.08.
On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.
On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96.
On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.

Phibro Animal Health Trading Up 3.4%

NASDAQ PAHC opened at $51.17 on Tuesday. The firm has a 50 day simple moving average of $46.57 and a 200-day simple moving average of $42.40. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 0.76 and a beta of 0.73.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health's dividend payout ratio is currently 21.33%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PAHC. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings restated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Zacks Research raised Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $37.50.

Check Out Our Latest Report on PAHC

Hedge Funds Weigh In On Phibro Animal Health

Several large investors have recently bought and sold shares of PAHC. Caitlin John LLC acquired a new stake in Phibro Animal Health in the fourth quarter valued at $266,000. Mackenzie Financial Corp boosted its position in shares of Phibro Animal Health by 7.1% during the 4th quarter. Mackenzie Financial Corp now owns 50,619 shares of the company's stock worth $1,895,000 after acquiring an additional 3,355 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Phibro Animal Health by 125.4% in the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company's stock valued at $606,000 after acquiring an additional 9,032 shares during the last quarter. Zacks Investment Management increased its holdings in shares of Phibro Animal Health by 13.2% in the 4th quarter. Zacks Investment Management now owns 91,391 shares of the company's stock valued at $3,414,000 after acquiring an additional 10,642 shares during the last quarter. Finally, VARCOV Co. acquired a new stake in shares of Phibro Animal Health during the 4th quarter worth about $672,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.